BLS

Breathe Life Sciences (BLS) is a leading international life sciences and pharmaceutical company specializing in the manufacture and distribution of alternative medicines, including medicinal cannabis, MDMA, and psilocybin. Headquartered in Sydney, Australia, and operating as a wholly-owned subsidiary of Bioxyne Limited (ASX: BXN), BLS is a GMP-licensed manufacturer with facilities in Australia, the UK, Japan, and Europe. The company provides a comprehensive suite of services including contract manufacturing (CDMO), white-label product development, and wholesale distribution of active pharmaceutical ingredients (API). BLS is notably the first Australian company to receive a GMP license for the commercial manufacture of MDMA and psilocybin, positioning it as a pioneer in the emerging field of psychedelic-assisted therapy. Its consumer-facing brand, Dr Watson®, offers a range of CBD and wellness products across global markets.